Digital PCR workflow and products

The QIAcuity Digital PCR System is a microfluidic nanoplate-based digital PCR (dPCR) platform that enables all the necessary steps for dPCR - partitioning, thermal cycling, and imaging/data acquisition - on a single instrument.

Request a demo

The QIAcuity ecosystem

While using a QIAcuity Digital PCR System is a great foundation, it takes an ecosystem of supporting accessories, kits and assays for your digital PCR reaction to truly flourish.

How does QIAcuity work?

Just like in qPCR experiments, preparation includes the transfer of mastermix, probes and primers, followed by the samples to a nanoplate. The time from system start to results is less than 2 hours. Data analysis on the QIAcuity Software Suite provides the concentration in copies per microliter of your target sequence and any quality controls. Analysis can also be performed on remote devices within the same LAN.

Watch tutorials

Enhancing your QIAcuity dPCR experience

How to choose a QIAcuity Digital PCR System

Together with its nanoplates, kits and assays, each instrument delivers high performance and data quality, with flexible throughput and multiplexing. Ask the right questions to evaluate your needs.

What applications will you perform most frequently?
Which instrumentation options best enable your scale of study?
What are the costs for product care beyond the initial investment?

Download brochure

For further guidance about comprehensive product care when making your decision, download the QIAcuity Service Brochure.

Publications

Browse a growing list of articles featuring QIAcuity dPCR products.

Delporte M, et al. Integrative assessment of total and intact HIV-1 reservoir by a 5-region multiplexed rainbow DNA digital PCR assay. Clinical Chemistry. 2025;71(1):203–214.

Ferrara D, et al. MicroRNAs in seminal plasma are able to discern infertile men at increased risk of developing testicular cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13784

Amman F, et al. Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale. Nature Biotechnology. 2022;40:1717–1723. doi:10.1038/s41587-022-01387-y

QIAcuity dPCR
–
FAQs

*FDA ‘Medical Devices; Laboratory Developed Tests’ final rule, May 6, 2024 and European Union regulation requirements on ‘In-House Assays’ (Regulation (EU) 2017/746 -IVDR- Art. 5(5))

The QIAcuity dPCR System is intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease. Therefore, the performance characteristics of the product for clinical use (i.e., diagnostic, prognostic, therapeutic or blood banking) is unknown.

The QIAcuityDx dPCR System is intended for in vitro diagnostic use, using automated multiplex quantification dPCR technology, for the purpose of providing diagnostic information concerning pathological states.

QIAcuity and QIAcuityDx dPCR instruments are sold under license from Bio-Rad Laboratories, Inc. and exclude rights for use with pediatric applications.